Medicare AdvantagePrior AuthMedium impact
Lynozyfic (linvoseltamab-gcpt) (New)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Sep 24, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Lynozyfic (linvoseltamab-gcpt), a new cancer drug for multiple myeloma patients. Coverage requires specific criteria including relapsed/refractory disease and at least four prior therapies.
Action Required
By September 24, 2025: Oncology providers must obtain prior authorization from Humana Medicare Advantage before prescribing Lynozyfic (linvoseltamab-gcpt) for multiple myeloma patients. Update EMR templates to document required criteria: relapsed/refractory disease, at least four prior therapies (proteasome inhibitor, immunomodulatory agent, anti-CD38 antibody), and single-agent use. Verify patients haven't progressed on prior BCMA-directed therapy. Claims will be denied without proper authorization.